Feeds:
Posts
Comments

Posts Tagged ‘fosamax’

*****

TODAY’S NEWS

What about those bone fracture risks with biophosphonate drugs? The jury is still out – A new study gives reassuring news about the safety of Fosamax and Reclast, bone-building drugs taken by millions of American women. It found that long-term use does not significantly raise the risk of a rare type of fracture near the hipmore

Monthly hepatitis C treatment looking promising – Human Genome Sciences Inc. said Wednesday a midstage study of the potential hepatitis C treatment Zalbin showed a monthly dose of the drug candidate could be as effective as a weekly dose of the standard treatment. The Rockville, Md., company said interim results from the study support evaluation of the monthly dose in a bigger, late-stage trial. The midstage study was conducted by Novartis, which is developing the drug with Human Genome Sciences. It combined the drug with ribavirin in 391 patients with forms of chronic hepatitis Cmore

Massive Multaq Mess Might Mean Major Meltdown – The scale of Sanofi-Aventis (SNY)’s Multaq mess is starting to become apparent: The heart drug, hailed by the company as a €1 billion-plus blockbuster prior to its launch, may miss Wall Street sales estimates by as much as €1.3 billion, according to analysts at Jefferies International. When investors wake up and downgrade their expectations for the atrial fibrillation drug, Sanofi’s stock may suffer, they say…more

Genzyme - feeling fines.

RECOMMENDED

Employee Assessment – including Executive Management assessment – Impactiviti’s vendor/partners have just what you need for top assessment programs and services.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Another reason to like Gilead Sciences (besides the fact that they have the best logo in the industry) – they actually have a rational pay plan for their top executive. What would it look like if pharma upper executive pay were based on annual performance for these measures: Profitability ratio (earnings vs. # of employees – something Gilead excels at, by the way); company share increase over a 3-year running average; and regulatory compliance? We might then see real pay-for-performance!

JUST FOR FUN

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS

Forbes: Pfizer‘s history of buying pipeline lemons. This does only tell one side of the story, however – Pfizer has also acquired some pretty major hits.

Speaking of flops, a couple of major experimental drugs aren’t looking so hot these days.

FDA taking another look at some bone drugs, in relation to hip fractures – There have long been safety questions — and lawsuits — over whether bone-building drugs like Merck’s Fosamax can actually increase the chance of femur fractures. Today, the FDA said it was going to take another look at the safety issuesmore

Did J&J plan to break the rules with Risperdal? Business Week reports. Plus, Shire gets a “fourfecta” warning letter from the FDA on one marketing promotion.

RECOMMENDED

Meetings/Events/Launches – Looking for creative and successful providers who can help make your off-site events a hit? We’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Nine Simple Steps to Getting Started in Social Media. Good stuff from Dose of Digital blog. For a practical guide on how YOU (as an individual) can put social networking to use building your own Opportunity Network, download my free e-book on that subject.

JUST FOR FUN

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

***

Read Full Post »

Lessons from Heath Ledger’s tragic death: Don’t mix prescription drugs.

Merck hands over a cool $649 million to settle allegations about marketing transgressions. Also, launches authorized generic of Fosamax, which lost patent protection this month.

GSK continues slumping due to Avandia decline.

Some Q&A about that recent diabetes study that was halted due to deaths in the (intensive sugar reduction) treatment arm.

Botox and deaths. Careful out there!

A vaccine for high blood pressure? This looks pretty intriguing!

Eisai fails to get a shot at early approval for a new cancer drug.

Promising new Schering drug (vicriviroc) may help suppress HIV when used in combination with older drugs.

Read Full Post »

As is becoming a more common event, this week’s news posting is being composed from an airport hotel room. My NJ ASTD colleagues are networking at the Annual Technology Training Showcase in Bridgewater; I’m in Chicago watching UConn stomp Gardner-Webb in basketball – oh, well.

It’s been another noisy week in pharma, mainly with the blacker black box for Avandia (see links below).

With GSK‘s Avandia woes deepening, Takeda is about to launch an advertising blitz for Actos. Meanwhile, GSK experiments with new selling models (including fewer sales reps, of course…)

Why restrict rough product news to one Top 5 company? Sanofi‘s Acomplia gets another cloud perched over it.

Reorganization is in the air, at least in New Brunswick. Changes at J&J.

Good news Bad news for Roche. Good news – anemia drug approved by FDA! Bad news – can’t sell it…

I’m sorry. Really. Here’s a $135 million apology.

Samples for sale! Go directly to…

Forteo goes one up on Fosamax.

Door locked in Pittsburgh. Another Med. Ctr. restricts drug reps.

Not necessarily news, but a nice resource I just came across. Selling Power’s Pharmaceutical Newsletter (free registration).

Read Full Post »

Follow

Get every new post delivered to your Inbox.

Join 27 other followers